Deucravacitinib: all 73 studies that test it

Page 1 of 1. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.

• Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study CompletersNot yet recruitingNCT07791199Phase 3
• Deucravacitinib in the Treatment of Cicatricial AlopeciasRecruitingNCT07508488Phase 2
• Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingNCT07352566Phase 4
• Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic DiseaseRecruitingNCT07280702Phase 4
• Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)RecruitingNCT07116967Phase 3
• The Efficacy and Safety of Deucravacitinib in Takayasu's ArteritisNot yet recruitingNCT07013838Phase 4
• A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque PsoriasisRecruitingNCT06979453Phase 3
• A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132RecruitingNCT06875960Phase 4
• A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic ArthritisRecruitingNCT06869551Phase 3
• Correction of Psoriatic T Cell Signatures by DeucravacitinibRecruitingNCT05858645Phase 4
• A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque PsoriasisRecruitingNCT04772079Phase 3
• A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female ParticipantsCompletedNCT06476834Phase 4Results posted
• Deucravacitinib (BMS-986165) for Pityriasis Rubra PilarisCompletedNCT06444399Phase 2Results posted
• A Study of Deucravacitinib to Treat LPP and FFACompletedNCT06091956Phase 2Results posted
• A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital PsoriasisTerminatedNCT06042920Phase 4Results posted
• Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).TerminatedNCT05997277Phase 2Results posted
• Deucravacitinib for the Treatment of Palmoplantar PustulosisTerminatedNCT05710185Phase 4Results posted
• A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community SettingCompletedNCT05701995Phase 4Results posted
• A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia AreataTerminatedNCT05556265Phase 2Results posted
• Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp PsoriasisCompletedNCT05478499Phase 4Results posted
• A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic DrugsActive, not recruitingNCT04908202Phase 3Results posted
• A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor TreatmentActive, not recruitingNCT04908189Phase 3Results posted
• A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative ColitisCompletedNCT04877990Phase 2Results posted
• A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)Active, not recruitingNCT04857034Phase 2Results posted
• A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative ColitisCompletedNCT04613518Phase 2Results posted
• An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South KoreaCompletedNCT04167462Phase 3Results posted
• An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus NephritisTerminatedNCT03943147Phase 2Results posted
• Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative ColitisCompletedNCT03934216Phase 2Results posted
• An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe PsoriasisCompletedNCT03924427Phase 3Results posted
• Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus ErythematosusCompletedNCT03920267Phase 2Results posted
• Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)CompletedNCT03881059Phase 2Results posted
• Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With PsoriasisCompletedNCT03624127Phase 3Results posted
• An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque PsoriasisCompletedNCT03611751Phase 3Results posted
• An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's DiseaseTerminatedNCT03599622Phase 2Results posted
• An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus ErythematosusCompletedNCT03252587Phase 2Results posted
• Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe PsoriasisCompletedNCT02931838Phase 2Results posted
• Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar PustulosisTerminatedNCT07000630Not applicable
• Tyrosine Kinase 2 (TYK2) for GA and CSWithdrawnNCT06725264Phase 2
• Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy ParticipantsCompletedNCT06566768Phase 1
• Deucravacitinib RosaceaWithdrawnNCT06532136Phase 2
• A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)CompletedNCT06333860Phase 4
• Vitiligo Treatment by Targeting TYK2 Mediated ResponsesActive, not recruitingNCT06327321Phase 2
• TYK2 Inhibition in Paradoxical PsoriasisTerminatedNCT06281106Phase 2/3
• A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory GenodermatosesCompletedNCT06136403Phase 2
• A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's SyndromeActive, not recruitingNCT05946941Phase 3
• Deucravacitinib in PGWithdrawnNCT05821374Early Phase 1
• A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus ErythematosusActive, not recruitingNCT05620407Phase 3
• A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)Active, not recruitingNCT05617677Phase 3
• An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail PsoriasisCompletedNCT05124080Early Phase 1
• Effect of BMS-986165 on the Blood Levels of MetforminCompletedNCT04671953Phase 1
• A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy ParticipantsCompletedNCT04536961Phase 1
• A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult ParticipantsCompletedNCT04305899Phase 1
• Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy ParticipantsCompletedNCT04249284Phase 1
• An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.CompletedNCT04086719Phase 1
• A Study to Determine the Pharmacokinetic Profile of BMS-986165 TabletsCompletedNCT04065932Phase 1
• A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy ParticipantsCompletedNCT04055506Phase 1
• Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With PsoriasisCompletedNCT04036435Phase 3
• A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy ParticipantsCompletedNCT03979248Phase 1
• Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese SubjectsCompletedNCT03956953Phase 1
• Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165CompletedNCT03930602Phase 1
• An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver DamageCompletedNCT03890809Phase 1
• A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.CompletedNCT03890770Phase 1
• Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy MalesCompletedNCT03873415Phase 1
• A Taste Assessment of BMS-986165 in Healthy ParticipantsCompletedNCT03751228Phase 1
• An Investigational Study to Evaluate Experimental Medication BMS-986165 Given as a Tablet and Solution in Healthy Male ParticipantsCompletedNCT03739788Phase 1
• An Investigational Study of Experimental Medication BMS-986165 in Healthy ParticipantsCompletedNCT03660436Phase 1
• An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram EffectsCompletedNCT03541564Phase 1
• An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male ParticipantsCompletedNCT03419910Phase 1
• A Study to Investigate BMS-986165 and Methotrexate in Healthy Male PatientsCompletedNCT03402087Phase 1
• The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female PatientsCompletedNCT03262727Phase 1
• A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet FormulationCompletedNCT03254784Phase 1
• Effect of BMS-986165 on the Pharmacokinetics of RosuvastatinCompletedNCT03044873Phase 1
• Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male ParticipantsCompletedNCT03004768Phase 1

← Deucravacitinib overview